Document is current
Any future updates will be listed below
-
Authors
Watzker, Anna https://orcid.org/0009-0003-8897-9339
Alsumali, Adnan
Ferro, Christine
Li, Xun Jun
Dieguez, Gabriela
Park, Clare
Chevure, Jestinah
Lautsch, Dominik
El-Kersh, Karim
-
Funding
Funding for this research was provided by:
Merck
- License Information
-
More Information
Article History
Received: 13 March 2025
Accepted: 24 April 2025
First Online: 30 May 2025
Declarations
:
: Anna Watzker, Adnan Alsumali, Xun Jun Li, and Dominik Lautsch are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA at time of manuscript submission. Christine Ferro, Gabriela Dieguez, and Clare Park are employees of Milliman, Inc., who received consulting fees from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Jestinah Chevure is an employee of MSD (UK) Limited, a subsidiary of Merck & Co., Inc., London, UK at time of manuscript submission. Karim El-Kersh participated in United Therapeutics speaker’s bureau 2018–2021 and served on advisory boards and as a consultant for United Therapeutics, J&J Actelion, Acceleron, and Merck & Co., Inc., Rahway, NJ, USA.
: This article is based on commercially available de-identified secondary data. Therefore, the study did not require patient IRB/EC review and approval. The study did not require patient informed consent. This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.
